2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. FOXM1

FOXM1

Forkhead box protein M1

Forkhead box protein M1 (FOXM1, also known as Trident, WIN, HFH-11, and MPP2; 27-30) is a member of the FOX family of transcription factors. The expression and activity of FoxM1 is important for the correct coupling of DNA synthesis to mitosis. FOXM1 is ubiquitously expressed in all proliferating mammalian cells, with its expression levels rising at the start of DNA synthesis and persisting until the end of mitosis. In M-phase, FOXM1 is phosphorylated and degraded before M-phase exit. FOXM1 has been suggested to play a role in normal coupling of S-phase to M-phase during cell cycle progression. FOXM1 enhances tumor metastasis in lung carcinoma, breast adenocarcinoma, pancreatic carcinoma, prostate carcinoma, colorectal cancer, ovarian carcinoma, cervical and nasopharyngeal carcinoma, ESCC and glioma[1][2].

FOXM1 Related Products (18):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0990
    Thiostrepton
    		Inhibitor 99.80%
    Thiostrepton is a thiazole antibiotic which selectively inhibits FOXM1. FOXM1 binds to YAP/TEAD complex. YAP/TEAD/FOXM1 complex binding at regulatory regions of genes governing cell cycle may impact cell proliferation.
    Thiostrepton
  • HY-112721
    FDI-6
    		Inhibitor 99.60%
    FDI-6 is an inhibitor of FOXM1. FDI-6 binds directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation.
    FDI-6
  • HY-19979
    RCM-1
    		Inhibitor 98.56%
    RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC50 of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research.
    RCM-1
  • HY-158420
    STL001
    		Inhibitor 99.81%
    STL001 is potent and selective FOXM1 inhibitor. STL001 induces the translocation of nuclear FOXM1 to the cytoplasm and promotes its autophagic degradation. STL001 sensitizes human cancers to a broad-spectrum of cancer therapies.
    STL001
  • HY-148530
    YX-2-107
    		Inhibitor 98.60%
    YX-2-107 is a PROTAC (IC50= 4.4 nM) that selectively degrades CDK6. YX-2-107 effectively inhibits RB phosphorylation and FOXM1 expression in vitro and inhibits the development of Ph+ ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
    YX-2-107
  • HY-181076
    FOXM1-IN-3
    		Inhibitor
    FOXM1-IN-3 is a potent FOXM1 inhibitor. FOXM1-IN-3 downregulates FOXM1 expression at protein and mRNA levels, suppressing downstream effectors CCNB1 and CDC25. FOXM1-IN-3 induces G2/M cell cycle arrest and apoptosis in colorectal cancer cells. FOXM1-IN-3 inhibits colony formation and cell migration in colorectal cancer cells. FOXM1-IN-3 targets the cancer stem cell phenotype in colorectal cancer cells, reducing cancer stem cell marker expression. FOXM1-IN-3 reduces tumor growth in a zebrafish xenograft model. FOXM1-IN-3 can be used for the research of colorectal cancer.
    FOXM1-IN-3
  • HY-182285
    5-HT7 modulator-1
    		Inhibitor
    5-HT7 modulator-1 is a selective 5-HT7 receptor antagonist with a Ki of 92 nM. 5-HT7 modulator-1 blocks 5-HT7 receptor signaling to reduce FOXM1, phosphorylated FOXM1, cyclin B1, and cdc25B levels. 5-HT7 modulator-1 acts as an antiproliferative, clonogenic inhibitor, and cell cycle inhibitor that induces G2/M arrest, reduces G0/G1 population. 5-HT7 modulator-1 can be used for the research of triple-negative breast cancer.
    5-HT7 modulator-1
  • HY-151986
    FOXM1-IN-1
    		Inhibitor 99.86%
    FOXM1-IN-1 is a potent FOXM1 inhibitor with an IC50 value of 2.65 µM. FOXM1-IN-1 shows antiproliferative activity. FOXM1-IN-1 decreases the the expression of FOXM1, PLK1, CDC25B protein.
    FOXM1-IN-1
  • HY-P11228
    FPP29
    		Degrader 99.20%
    FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)).
    FPP29
  • HY-P1687
    Siomycin A
    		Inhibitor
    Siomycin A is a thiopeptide antibiotic and is a Forkhead box M1(FOXM1) selective inhibitor without affecting other members of the Forkhead box family. Siomycin A has anti-tumor and promotes apoptosis.
    Siomycin A
  • HY-170552
    KC12
    		Inhibitor
    KC12 is an inhibitor for FOXM1 transcription factor. KC12 exhibits cytotoxicity in cancer cell MDA-MB-231 with an IC50 of 6.13 µM.
    KC12
  • HY-178462
    Hsp70/FoxM1-IN-1
    		Inhibitor
    Hsp70/FoxM1-IN-1 (Compound 7d) is a potent heat shock protein 70 (Hsp70) and Forkhead box M1 (FoxM1) dual inhibitor. Hsp70/FoxM1-IN-1 demonstrates significant antiproliferative and pro-apoptotic effects in multiple solid tumor models (e.g., breast, colorectal cancer), particularly for tumors co-overexpressing Hsp70/FoxM1.
    Hsp70/FoxM1-IN-1
  • HY-P11494
    AWWNTEW
    		Ligand
    AWWNTEW (CP29) is a FOXM1-DBD peptide ligand with cytotoxicity to cancer cells. AWWNTEW has a strong affinity and binds to the FOXM1 protein. AWWNTEW is a component of FPP29 (HY-P11228). X
    AWWNTEW
  • HY-150038
    NOSH-aspirin
    		Inhibitor
    NOSH-aspirin (NBS-1120) is an orally active hybrid molecule that releases nitric oxide and hydrogen sulfide. NOSH-aspirin inhibits pancreatic cancer cell proliferation and induces apoptosis. NOSH-aspirin inhibits cancer cell growth and suppresses NF-κB and FoxM1 in a mouse model of pancreatic cancer. NOSH-aspirin also alleviates motor deficits and dopaminergic neuron degeneration in a rat model of Parkinson's disease. NOSH-aspirin reduces neuroinflammation caused by microglial and astrocytic activation. NOSH-aspirin can be used in research on cancers such as pancreatic cancer and neurological diseases such as Parkinson's disease.
    NOSH-aspirin
  • HY-161617
    LASSBio-2052
    		Inhibitor
    LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC). LASSBio-2052 inhibits HCC cells HepG2 and Hep3B, with IC50 of 18 and 41 μM. LASSBio-2052 arrests the cell cycle at G2/M phase, through downregulation of FOXM1. LASSBio-2052 induces apoptosis in HCC cells.
    LASSBio-2052
  • HY-156609
    FOXM1-IN-2
    		Inhibitor
    FOXM1-IN-2 is a FOXM1 inhibitor, with antineoplastic activity.
    FOXM1-IN-2
  • HY-112509
    STL427944
    		Inhibitor
    STL427944 is a potent and selective FOXM1 inhibitor. STL427944 has the potential for the research of overcoming tumor chemoresistance.
    STL427944
  • HY-N19821
    Gangaleoidin
    		Inhibitor
    Gangaleoidin is a FOXM1 inhibitor with an IC50 of 2.8 μM. Gangaleoidin inhibits interaction between FOXM1’s DNA-binding domain and target DNA sequence, downregulates FOXM1 and downstream target gene CCNB1 at the transcriptional level. Gangaleoidin suppresses proliferation of FOXM1-overexpressing breast cancer cells. Gangaleoidin can be used for the research of breast cancer.
    Gangaleoidin